Clinical trials: Lung Metastases
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Non-small Cell Lung Cancer Stage II, Bevacizumab
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases
- Conditions
- Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases
- Trial name
- SUPER BRAIN (NCT05807893)
- Testing
- Serplulimab combined with bevacizumab and first-line chemotherapy
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-Small-Cell Lung Cancer, Brain Metastases
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
- Trial name
- NCT06476093
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Breast Cancer, Lung Cancer
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Head and Neck Cancer
- Trial name
- POSITive (NCT06321640)
- Testing
- Cohort A: primarily operable disease, candidate to adjuvant, Cohort B: locally advanced disease, Cohort C: metastatic disease
- Where
- Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Pleural Diseases, Pleural Mesothelioma
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
The PROSPECT study aims to look at the number of problems or side effects which occur after patients have had a procedure completed to remove fluid or air from the space between the lung and the chest wall.
- Conditions
- Pleural Diseases, Pleural Mesothelioma, Pneumothorax, Pleural Effusion
- Trial name
- PROSPECT (NCT05910112)
- Testing
- Pleural interventions
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Multiple Brain Metastases, Non-small-cell Lung Cancer
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as first-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone. 2.
- Trial name
- NCT01887795
- Testing
- Erlotinib, WBRT
- Where
- China
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Small Cell Lung Cancer, Brain Metastases
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
1. Compare the effect and safety of gefitinib alone with gefitinib plus concomitant WBRT(whole-brain radiotherapy ) in treatment of NSCLC patients harboring an EGFR mutation with multiple BM. 2.
- Conditions
- Non-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
- Trial name
- EGFR (NCT02338011)
- Testing
- Gefitinib, WBRT
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer, Bone Metastases
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone…
- Trial name
- BLEST (NCT00765687)
- Testing
- bisphosphates
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University